Adjuvant Therapy
The evolution of adjuvant therapy has created tectonic shifts in the field—opening a range of not only treatment options but also discussion points to which the medical, research, and advocacy community are split - Melanoma Research Institute

image by: HWN
HWN Suggests
Adjuvant Therapy: How Much Do Patients Really Need?
Yet a conundrum remains: Although adjuvant therapy clearly extends remissions in some patients, the additional treatment may not always be needed to achieve a cure and may sometimes even be harmful. For others, the added treatment may do little to prevent cancer from coming back. Now, new tools, such as DNA sequencing-based tests that detect circulating tumor DNA (ctDNA), are poised to better define who might benefit from adjuvant therapy. The new tests do more than just catalog defects in cancer genes. They collect the entire universe of DNA sequence changes that accumulate throughout the cancer cell genome and use this information to create an individualized “ultrasensitive” test.Featured
Adjuvant Therapy: Is More Better or is Less More?
Adjuvant therapy, however, is not without its side effects and risks. Mild side effects can include nausea, fever, diarrhea, and fatigue. Although less common but serious, non-reversible side effects can also include diabetes, thyroid conditions, as well as skin, gastrointestinal, and lung reactions. The evolution of adjuvant therapy has created tectonic shifts in the field—opening a range of not only treatment options but also discussion points to which the medical, research, and advocacy community are split.
Articles of Interest
Adjuvant Therapy in Cancer: Benefits, Types, Timing, and Precision-Based Innovations
Adjuvant therapy has become a cornerstone of modern oncologic care, representing a proactive approach to reducing cancer recurrence and improving long-term outcomes. Defined as treatment administered after the primary modality—most often surgery—adjuvant therapy aims to eliminate microscopic residual disease that may not be clinically detectable but poses a risk for future metastasis. Unlike neoadjuvant therapy, which is given before the main treatment to shrink tumors or enable resection, or palliative therapy, which focuses on symptom relief in advanced disease, adjuvant therapy is typically curative in intent.
Adjuvant Therapy: Should You Receive It?
Doctors hope one day to have a test to determine the odds that a patient would benefit from a given treatment before it is offered. For instance, patients with tumors that express a protein called ERCC1 might not benefit from chemotherapy. However, tests for the protein are not extremely reliable as they frequently yield both false positives and negatives. Researchers continue to search for other biomarkers that might aid in treatment decisions.
Editorial: Risks and Benefits of Adjuvants to Cancer Therapies
Cancer patients may have minimal residual disease after completing primary treatment, which could be a source of subsequent early recurrence and metastasis. Adjuvant therapy (including chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy) has the potential to remove minimal residual disease and increase patient survival. In contrast, neoadjuvant therapy is utilized to shrink tumors prior to the primary treatment. Ongoing research in the fields of adjuvant and neoadjuvant cancer therapy is expected to yield new drugs and innovative approaches that can be combined with existing therapies to improve patient outcomes and prevent cancer recurrence.

